Fundz

Bicara Therapeutics Announces Oversubscribed $165 Million Series C Financing

PUBLIC · BCAXDec 12, 2023

Amount Raised

$165 Million

Round Type

Series C

BostonBiotechnologyHealth CareTherapeutics

Investors

Stern Investor RelationsTpg LsiCarolyn Ng, Ph.D., Business Unit PartnerAisling CapitalFairmountDeerfield ManagementThe Rise FundTPG Life Sciences InnovationsTpgBraidwell LP

Description

Bicara Therapeutics, a clinical-stage biotechnology company developing dual-action biologics to elicit a potent and durable immune response, today announced the completion of an oversubscribed $165 million Series C financing. The financing was co-led by Braidwell LP and TPG, which is investing in the company through TPG Life Sciences Innovations (TPG LSI) and The Rise Fund, with additional new investors including Deerfield Management, Fairmount, Aisling Capital and a leading biotechnology investor associated with one of the largest alternative asset managers. All existing Series B investors also participated in the round.

Who else raised in Therapeutics and Biotechnology around the same time

Companies in the same sectors as Bicara Therapeutics that raised within 45 days of this round, from Fundz verified event records.

  • Calidi Biotherapeutics raised $1M on January 26, 2024.
  • Alpha Cognition raised $2.8M (Seed) on January 24, 2024.
  • Calluna Pharma raised $82M (Series A) on January 23, 2024.
  • BridgeBio raised $1.3B on January 22, 2024.
  • Calidi Biotherapeutics raised $10K on January 19, 2024.
  • Ratio Therapeutics raised $50M (Series B) on January 17, 2024.

Who to call at Bicara Therapeutics, and when

A new round usually means Bicara Therapeutics is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day Bicara Therapeutics raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Bicara Therapeutics, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Bicara Therapeutics. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Bicara Therapeutics

Location

Boston, Massachusetts, United States

About

Bicara Therapeutics is a clinical-stage biotechnology company developing first-in-class biologics engineered to combine the precision of well validated, tumor-targeting antibodies with the power of tumor microenvironment modulators. The company’s bifunctional antibodies are designed to deliver an immunomodulatory payload directly to the tumor microenvironment to ramp up immune cell activity, offering the potential for synergistic therapeutic impact at the site of the tumor. Bicara’s lead product candidate, BCA101, is a first-in-class EGFR/TGF-β-trap bifunctional antibody currently being evaluated in a Phase 1/1b study. For more information, please visit www.bicara.com or follow us on LinkedIn or Twitter.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Bicara Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

1 contact
Predictive Intelligence
Strategic

ML-powered predictions for Bicara Therapeutics's next move

See what Strategic adds

Bicara Therapeutics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.